Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations

Amyloid proteins have long been in the spotlight for being involved in many degenerative diseases including Alzheimer´s, Parkinson´s or type 2 diabetes, which currently cannot be prevented and for which there is no effective treatment or cure. Here we provide a comprehensive review of inhibitors tha...

Descripción completa

Detalles Bibliográficos
Autores: López-García, Paula, Tejero-Ojeda, María M., Vaquero, María Eugenia, Carrión-Vázquez, Mariano Sixto
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/402755
Acceso en línea:http://hdl.handle.net/10261/402755
https://api.elsevier.com/content/abstract/scopus_id/86000746021
Access Level:acceso abierto
Palabra clave:Amyloid disease
Amyloid inhibitor
Functional amyloid
Neurodegenerative disease, Nanomaterials
Pathological amyloid
id ES_bbf8d9452c020659d7dbc8aedbefea13
oai_identifier_str oai:digital.csic.es:10261/402755
network_acronym_str ES
network_name_str España
repository_id_str
spelling Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovationsLópez-García, PaulaTejero-Ojeda, María M.Vaquero, María EugeniaCarrión-Vázquez, Mariano SixtoAmyloid diseaseAmyloid inhibitorFunctional amyloidNeurodegenerative disease, NanomaterialsPathological amyloidAmyloid proteins have long been in the spotlight for being involved in many degenerative diseases including Alzheimer´s, Parkinson´s or type 2 diabetes, which currently cannot be prevented and for which there is no effective treatment or cure. Here we provide a comprehensive review of inhibitors that act directly on the amyloidogenic pathway (at the monomer, oligomer or fibril level) of key pathological amyloids, focusing on the most representative amyloid-related diseases. We discuss the latest advances in preclinical and clinical trials, focusing on cutting-edge developments, particularly on nanomaterials-based inhibitors, which offer unprecedented opportunities to address the complexity of protein misfolding disorders and are revolutionizing the landscape of anti-amyloid therapeutics. Notably, nanomaterials are impacting critical areas such as bioavailability, penetrability and functionality of compounds currently used in biomedicine, paving the way for more specific therapeutic solutions tailored to various amyloid-related diseases. Finally, we highlight the window of opportunity opened by comparative analysis with so-called functional amyloids for the development of innovative therapeutic approaches for these devastating diseases.This work was supported by grants from the Spanish Ministry of Science and Innovation (MICINN: PID2020-117847RB-I00/AEI/10.13039/501100011033 and the Spanish Research Council (CSIC: PIE 202420E226) to MC-V. PL-G was funded by an Industrial Doctorate fellowship from the Community of Madrid associated to DisruPep SL and CSIC (IND2020/BMD-17444).Peer reviewedElsevierAgencia Estatal de Investigación (España)Ministerio de Ciencia e Innovación (España)Consejo Superior de Investigaciones Científicas (España)Comunidad de MadridVaquero, María Eugenia [0000-0003-3277-5532]Carrión-Vázquez, Mariano Sixto [0000-0001-7319-406X]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202520252025info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/402755https://api.elsevier.com/content/abstract/scopus_id/86000746021reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttps://doi.org/10.1016/j.pneurobio.2025.102734Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/4027552026-05-22T06:33:51Z
dc.title.none.fl_str_mv Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations
title Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations
spellingShingle Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations
López-García, Paula
Amyloid disease
Amyloid inhibitor
Functional amyloid
Neurodegenerative disease, Nanomaterials
Pathological amyloid
title_short Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations
title_full Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations
title_fullStr Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations
title_full_unstemmed Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations
title_sort Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations
dc.creator.none.fl_str_mv López-García, Paula
Tejero-Ojeda, María M.
Vaquero, María Eugenia
Carrión-Vázquez, Mariano Sixto
author López-García, Paula
author_facet López-García, Paula
Tejero-Ojeda, María M.
Vaquero, María Eugenia
Carrión-Vázquez, Mariano Sixto
author_role author
author2 Tejero-Ojeda, María M.
Vaquero, María Eugenia
Carrión-Vázquez, Mariano Sixto
author2_role author
author
author
dc.contributor.none.fl_str_mv Agencia Estatal de Investigación (España)
Ministerio de Ciencia e Innovación (España)
Consejo Superior de Investigaciones Científicas (España)
Comunidad de Madrid
Vaquero, María Eugenia [0000-0003-3277-5532]
Carrión-Vázquez, Mariano Sixto [0000-0001-7319-406X]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Amyloid disease
Amyloid inhibitor
Functional amyloid
Neurodegenerative disease, Nanomaterials
Pathological amyloid
topic Amyloid disease
Amyloid inhibitor
Functional amyloid
Neurodegenerative disease, Nanomaterials
Pathological amyloid
description Amyloid proteins have long been in the spotlight for being involved in many degenerative diseases including Alzheimer´s, Parkinson´s or type 2 diabetes, which currently cannot be prevented and for which there is no effective treatment or cure. Here we provide a comprehensive review of inhibitors that act directly on the amyloidogenic pathway (at the monomer, oligomer or fibril level) of key pathological amyloids, focusing on the most representative amyloid-related diseases. We discuss the latest advances in preclinical and clinical trials, focusing on cutting-edge developments, particularly on nanomaterials-based inhibitors, which offer unprecedented opportunities to address the complexity of protein misfolding disorders and are revolutionizing the landscape of anti-amyloid therapeutics. Notably, nanomaterials are impacting critical areas such as bioavailability, penetrability and functionality of compounds currently used in biomedicine, paving the way for more specific therapeutic solutions tailored to various amyloid-related diseases. Finally, we highlight the window of opportunity opened by comparative analysis with so-called functional amyloids for the development of innovative therapeutic approaches for these devastating diseases.
publishDate 2025
dc.date.none.fl_str_mv 2025
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/402755
https://api.elsevier.com/content/abstract/scopus_id/86000746021
url http://hdl.handle.net/10261/402755
https://api.elsevier.com/content/abstract/scopus_id/86000746021
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://doi.org/10.1016/j.pneurobio.2025.102734
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418072836669440
score 15,811543

Similares en LA Referencia